ADC Therapeutics S.A.

NYSE:ADCT

Biotechnology

Healthcare
$1.37 -1.35%

-$0.02 today

Market cap
$192.71M
Beta
1.77
P/E (TTM)
-1.2
EPS (TTM)
-$0.89
52W Low $0.78High $4.98

Volume 1.17M

Average 1.68M

ADCT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

ADC Therapeutics S.A.NYSE: ADCT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 154.14M shares rose 43.8% year over year, ahead of the +34.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +17.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +43.8% holds above the trailing-twelve-month pace of +34.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
154.14M+2.6% QoQ
Last fiscal yearDec 2025
127.07M+30.8% YoY
LTMMar 2026
138.66M+34.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+43.8%——
1 year+30.8%——
3-year CAGR+17.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
127.07M USD
Year-over-year change
+30.8%
4-year CAGR
+13.4%

Weighted Avg Shares vs competitors

How ADCT compares with its peers on the latest reported figures

  • ADCT's LTM Mar 2026 weighted avg shares of 138.66M shares is the 6th highest of the 10 companies compared; the peer median is 166.7M shares.
  • Its year-over-year change of +34.3% is the 2nd highest of 10, against a peer median of +7.9%.
  • Over three fiscal years its annual growth of +17.6% compares with a peer median of +21.4%.
ADCT Competitors Peer median
Weighted Avg Shares for ADCT and competitors
Company Period LTM YoY 3-year CAGR
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026372.59M +6.8%+29.9%
AUTLAutolus Therapeutics plcLTM Mar 2026266.14M +0.0%+41.0%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026233.09M +16.0%+10.7%
QSIQuantum-Si incorporatedLTM Mar 2026201.73M +31.6%+12.4%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.7%+384.0%
BCYCBicycle Therapeutics plcLTM Mar 202669.4M +7.1%+32.7%
OMEROmeros CorporationLTM Mar 202665.07M +12.1%+0.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
Peer median (excluding ADCT) 166.7M+7.9%+21.4%

Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.92M209.91M69.56M70.84M81.36M
Cost of Revenue1.39M3.3M2.53M5.95M7.67M
Gross Profit32.52M206.61M67.03M64.89M73.68M
Gross Margin95.9%98.4%96.4%91.6%90.6%
Research & Development158M186.46M127.13M109.63M104.01M
Selling, General & Admin136.24M143.49M105.89M85.91M(6.82M)
Operating Expenses294.24M329.95M233.02M195.54M182.06M
Depreciation & Amortization2.63M2.39M3.27M3.28M1.88M
EBITDA(230.54M)(107.7M)(145.83M)(102.65M)(89.27M)
EBITDA Margin-679.7%-51.3%-209.6%-144.9%-109.7%
Operating Income(261.72M)(123.34M)(165.99M)(130.65M)(108.38M)
Operating Margin-771.6%-58.8%-238.6%-184.4%-133.2%
Interest Income66K2.57M10.54M12.27M8.81M
Interest Expense18.34M36.73M46.33M50.21M51.63M
Other Income / Expenses10.22M(33.56M)(34.96M)(27.03M)(34.4M)
Income Before Tax(251.51M)(156.9M)(200.95M)(157.68M)(142.78M)
Pre-Tax Margin-741.5%-74.7%-288.9%-222.6%-175.5%
Income Tax Expense(21.48M)227K39.11M166K(157K)
Net Income(230.03M)(157.13M)(240.05M)(157.85M)(142.62M)
Net Margin-678.2%-74.9%-345.1%-222.8%-175.3%
EPS (Basic)(3.00)(1.99)(2.94)(1.62)(1.12)
EPS (Diluted)(3.00)(1.99)(2.94)(1.62)(1.12)
Weighted Avg Shares76.75M78.15M81.71M97.16M127.07M
Weighted Avg Shares (Diluted)76.75M78.15M81.71M97.16M127.07M

ADC Therapeutics S.A.

NYSE:ADCT

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.